论文部分内容阅读
目的探讨调节Ubc9基因对卵巢癌细胞侵袭和迁移能力的影响,探讨其作用机制。方法应用体外Transwell细胞侵袭实验检测调节Ubc9基因对卵巢癌HO8910细胞侵袭能力影响,以稳定转染Ubc9的HO8910-Ubc9细胞为Ubc9组,对照组为未转染的HO8910细胞(normal)及转染空质粒的HO8910细胞(vector);另以转染Ubc9特异性siRNA的HO8910-Ubc9细胞为siRNA1、siRNA2组,对照组为未被Ubc9特异性siRNA转染HO8910-Ubc9细胞(normal)及转染无关序列RNA的HO8910-Ubc9细胞(negative control)。应用划痕实验观察调节Ubc9基因对卵巢癌HO8910细胞迁移能力的影响。结果 HO8910-Ubc9组穿过Matrigel胶的细胞数量明显高于空白对照组和空质粒组(P<0.05),Ubc9-siRNAs转染48h后,HO8910-Ubc9细胞穿过人工基底膜的细胞数目明显低于对照组(P<0.05)。HO8910-Ubc9细胞在6、12、24h愈合率明显高于HO8910组(P<0.05),转染Ubc9-siRNA的HO8910-Ubc9细胞于划痕后在24h,细胞愈合率明显低于对照组(P<0.05)。结论 Ubc9促进HO8910细胞侵袭、迁移,可能成为临床治疗的新靶点。
Objective To investigate the effect of Ubc9 gene on invasion and migration of ovarian cancer cells and to explore its mechanism. Methods In vitro transwell invasion assay was used to detect the effect of Ubc9 gene on the invasiveness of ovarian cancer cell line HO8910. The cell line HO8910-Ubc9 stably transfected with Ubc9 was Ubc9 and the untransfected HO8910 cells were transfected Plasmid HO8910 cells (vector); another transfected Ubc9 specific siRNA HO8910-Ubc9 cells for siRNA1, siRNA2 group, the control group was not transfected with Ubc9 specific siRNA HO8910-Ubc9 normal (normal) and transfected unrelated sequences RNA of HO8910-Ubc9 cells (negative control). The effect of Ubc9 gene on the migration of ovarian cancer cells HO8910 was observed by scratch test. Results The number of cells passing through Matrigel in HO8910-Ubc9 group was significantly higher than that in blank control group and empty plasmid group (P <0.05). After transfected with Ubc9-siRNAs for 48h, the number of HO8910-Ubc9 cells passing through artificial basement membrane was significantly lower In the control group (P <0.05). The healing rate of HO8910-Ubc9 cells at 6, 12 and 24 hours was significantly higher than that of HO8910 group (P <0.05). The cell healing rate of HO8910-Ubc9 cells transfected with Ubc9-siRNA at 24 hours after wounding was significantly lower than that of the control group <0.05). Conclusion Ubc9 can promote the invasion and migration of HO8910 cells, which may be a new target for clinical treatment.